ctDNA-Based MRD Testing

Precise MRD Detection. Confident Decisions on Treatment and Surveillance.

LymphoVista delivers ctDNA results at the milestones that shape your clinical decisions — end of treatment, mid-cycle, and follow-up. Validated panels for B-cell and Hodgkin lymphoma.

Presented at ASH 2024 · EHA 2024

Order LymphoVista

Clinical Validation

93.86%

Sensitivity (B-Cell)

99.999%

Specificity

HR 6.9

Hazard Ratio — Hodgkin (p<0.0001)

Test Variants

Two Specialized Panels

LymphoVista offers disease-specific ctDNA assays optimized for B-cell lymphomas and Hodgkin lymphoma respectively. Select a variant to view its specifications and clinical evidence.

LymphoVista

For B-Cell Lymphomas

(D)LBCL Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Burkitt Lymphoma CNS Lymphomas

Limit of Detection (LoD): 6.69 × 10⁻⁶

18-month OS: 77% (MRD-neg) vs 33% (MRD-pos) — HR 4.61, p<0.0001

18-month PFS: 51% (MRD-neg) vs 5% (MRD-pos) — HR 4.32, p<0.0001

326 samples from 88 patients

See published survival data ↓

LymphoVista HL

For Hodgkin Lymphoma

Hodgkin Lymphoma (Classical) Hodgkin Lymphoma (Nodular)

Limit of Detection (LoD): 6.54 × 10⁻⁶

4-year PFS: 95.3% (MRD-2-neg) vs 72.2% (MRD-2-pos) — HR 6.9, p<0.0001

MRD-2-positive rate: 18.5%

Clinical Value

Four Decisions Enabled

MRD Detection Detect minimal residual disease earlier than imaging — often months before clinical relapse.

Therapy Monitoring Monitor treatment response continuously with ctDNA — adjust protocols based on real-time molecular data.

Early Relapse Detection Identify relapses months before radiological appearance — act while options are still broad.

Risk Stratification Stratify relapse risk accurately to guide personalized treatment decisions.

How It Works

Three Steps. Zero Complexity.

Genotyping

Send 20 ml blood in cfDNA tubes. We create a patient-specific mutation profile.

MRD Monitoring

Longitudinal ctDNA monitoring tracks disease burden over your treatment timeline.

Report & Interpretation

Receive a clear clinical report within 2–4 weeks. MRD status, trend, and clinical context included.

"Lymphoma patients deserve better than waiting for imaging to confirm what ctDNA can already tell you. That is why we built LymphoVista."

Dr. Sven Borchmann

Founder & CEO, LIQOMICS

Detect relapse. Earlier.

LymphoVista delivers clinical-grade MRD monitoring for lymphoma — contact us to discuss your patient cases.

Contact Our Team →

References

Mattlener et al. Presentation at American Society of Hematology (ASH) Annual Meeting 2024.
Schleifenbaum et al. Presentation at European Hematology Association (EHA) Annual Meeting 2024.